How to evaluate the experience of a writer in the field of pharmaceutical process optimization and validation within the healthcare and biomedical industry? The MBCM Research Council of the Netherlands project PDA-CMC was designed and evaluated in the platform. In this analysis, we focus on an operational issue related to this topic. While it would be advantageous to show the practical characteristics of this kind of testing, we provide only the description of the process, as defined by the MBCM RCP-EQ to enable assessment of this process, as well as guidance regarding other aspects of the process. We further discuss another technical points, firstly the issue of accuracy, to ensure that the platform does not indicate both error and production errors. Secondly, the test was approved for use in the MBCM project, as well as with MBCM-DIF analysis. We intend to demonstrate the feasibility of MBCM project development in the clinical practice. In conclusion, we present an attractive RCP-EQ report with the following features which include a description of the processes for testing the data and for presenting an operational assessment: 1. Testing the data and pre-disturbance testing 2. Validation of the data and pre-construction of pre-evaluation scenarios 3. Test the pre-evaluation scenario. We are grateful to all members of the staff who took part in this study. We would also like to thank the management team as well as the decision-makers in the various health-care delivery and environmental matters: EMM. Finally, we thanks the anonymous reviewers for their valuable comments and suggestions. 